Sep. 9 at 12:06 AM
Assembly Biosciences exercised its contractual option to participate in 40% of the U.S. development costs and profits from its herpes simplex virus (HSV) helicase-primase inhibitor program developed with Gilead Sciences. The decision followed Assembly Bio’s review of Gilead’s full development plan and budget for two investigational compounds, GS-1179 and GS-5366, which are being developed for recurrent genital herpes.
By choosing the profit-sharing arrangement, Assembly Bio will gain a significant share of the potential U.S. commercial opportunity while Gilead retains sole responsibility for clinical development and commercialization. Assembly Bio also remains eligible for up to
$280 million in regulatory and commercial milestones, plus tiered royalties on net sales outside the U.S.
The company reaffirmed that its cash runway extends through 2029, supported in part by a
$75 million collaboration extension fee from Gilead expected in the fourth quarter of 2026.
$ASMB